NASDAQ · AMRX
Amneal Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for AMRX: Nov 03, 2026
Amneal Pharmaceuticals, Inc. Class A Common Stock is expected to report earnings on 11/03/2026 before market open. The report will be for the fiscal Quarter ending Sep 2026. According to Zacks Investment Research, based on 2 analysts' forecasts, the consensus EPS forecast for the quarter is $0.23. The reported EPS for the same quarter last year was $0.15.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $0.23 | $0.23 | $0.22 | 2 |
| Dec 2026 | $0.22 | $0.22 | $0.21 | 2 |
| Mar 2027 | $0.24 | $0.24 | $0.24 | 1 |
| Jun 2027 | $0.28 | $0.28 | $0.28 | 1 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks- Zacks · Oct 30, 10:05 AM EDTGILD Beats Q3 Earnings on HIV Strength & Trodelvy Sales GrowthGilead tops Q3 earnings and revenue estimates as HIV sales, Trodelvy and Livdelzi drive growth, prompting an increase in 2026 product sales guidance.
- Zacks · Oct 30, 9:29 AM EDTINSM Q3 Earnings Miss, Stock Soars on Sales Beat & Raised GuidanceInsmed's third-quarter revenues surge 268%, fueled by strong Brinsupri sales, prompting a 15% stock rally and higher 2026 sales guidance.
- Zacks · Oct 30, 8:36 AM EDTHALO Gears Up to Report Q3 Earnings: Is a Beat in the Cards?Halozyme is poised for a Q3 earnings beat as strong demand for partnered drugs is likely to boost royalties and drive the top line.
- Zacks · Oct 29, 11:52 AM EDTVKTX Q3 Earnings Miss Estimates Amid Rising Clinical ExpensesViking Therapeutics' Q3 loss widens as rising costs weigh on results, while its obesity drug candidate advances through phase III studies.
- Zacks · Oct 29, 11:31 AM EDTAmarin's Q3 Earnings Beat Estimates, Revenues Miss MarkAMRN's Q3 2026 earnings surpass estimates despite declining revenues. Global Vascepa/Vazkepa demand grows 55% and cash reserves increase.
- Zacks · Oct 29, 9:43 AM EDTBHC Q3 Earnings Beat on Salix Growth, Stock Gains 9% as Outlook RisesBausch Health shares jump 9% as Q3 earnings top estimates, driven by Xifaxan-led Salix growth, improved profitability and raised 2026 guidance.
- Zacks · Oct 29, 7:35 AM EDTIndivior Pharmaceuticals Inc. (INDV) Beats Q3 Earnings and Revenue EstimatesIndivior Pharmaceuticals Inc. (INDV) delivered earnings and revenue surprises of +41.94% and +8.97%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?
- Zacks · Oct 28, 9:00 AM EDTBioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: What to Know Ahead of Next Week's ReleaseBioCryst (BCRX) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 9:00 AM EDTAmneal Pharmaceuticals (AMRX) Earnings Expected to Grow: Should You Buy?Amneal (AMRX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
- Zacks · Oct 27, 8:40 AM EDTIs Amneal Pharmaceuticals (AMRX) Stock Outpacing Its Medical Peers This Year?Here is how Amneal Pharmaceuticals (AMRX) and Iovance Biotherapeutics (IOVA) have performed compared to their sector so far this year.
- Zacks · Oct 27, 8:00 AM EDTImplied Volatility Surging for Amneal Pharmaceuticals Stock OptionsInvestors need to pay close attention to AMRX stock based on the movements in the options market lately.
- Zacks · Oct 26, 11:10 AM EDTWill Amneal (AMRX) Beat Estimates Again in Its Next Earnings Report?Amneal (AMRX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Amneal Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.